Regulatory Basis for U.S. Drug - U.S. Track - Document - PDFSEARCH.IO

First Page	Meta Content
	Regulatory Basis for U.S. Drug & Biologics Approval Paul G. Kluetz, M.D. Office of Hematology and Oncology Products Add to Reading List Open Document File Size: 63,89 KB Share Result on Facebook Company Diagnostic / Therapeutic Radiologics 3 Combination Products / In Vitro Diagnostics / / Country United States / / Event Reorganization / M&A / FDA Phase / / IndustryTerm therapy for the same disease / / MedicalCondition same disease / tumor / diseases / radiographic tumor / solid tumor / Breast Cancer / / MedicalTreatment alternative therapy / / Organization office of Hematology / Oncology Products Center for Biologics Evaluation and Research / FDA / Center for Drug Evaluation and Research / office of Hematology and Oncology Products / Vaccines Center for Devices and Radiologic Health / Hematology and Oncology Products Center for Biologics Evaluation and Research / FDA Mission / office of Combination Products / / Person Paul G. Kluetz / Cellular Therapies / Gene Therapies / / Product cytotoxic drug / / Technology Radiation / ultrasound / Antibodies / / SocialTag Clinical research Center for Devices and Radiological Health Center for Drug Evaluation and Research Biologic Center for Biologics Evaluation and Research Surrogate endpoint FDA Fast Track Development Program Clinical trial Federal Food, Drug, and Cosmetic Act Food and Drug Administration

Regulatory Basis for U.S. Drug & Biologics Approval Paul G. Kluetz, M.D. Office of Hematology and Oncology ProductsAdd to Reading List